Practice Guideline for Off-label Use of Immune Checkpoint Inhibitors

Zhejiang Pharmaceutical Association Anti-tumor Drug Professional Committee; Zhejiang Anticancer Association Tumor Clinical Pharmacy Professional Committee; Zhejiang Pharmaceutical Association Evidence-based Pharmacy Committee

doi:10.13748/j.cnki.issn1007-7693.20232878

Zhejiang Pharmaceutical Association Anti-tumor Drug Professional Committee, Zhejiang Anticancer Association Tumor Clinical Pharmacy Professional Committee, Zhejiang Pharmaceutical Association Evidence-based Pharmacy Committee. Practice Guideline for Off-label Use of Immune Checkpoint Inhibitors[J]. Chinese Journal of Modern Applied Pharmacy, 2024, 41(11): 1529-1542. DOI: 10.13748/j.cnki.issn1007-7693.20232878

Citation:

Practice Guideline for Off-label Use of Immune Checkpoint Inhibitors

Graphical Abstract

Graphical Abstract

Abstract

Abstract

OBJECTIVE To provide reference for the off-label use of immune checkpoint inhibitor(ICIs), and to promote the clinical rational use of ICIs.
METHODS A multi-disciplinary expert team was set up, and the practice guidelines was formed through many rounds of expert discussion on the basis of evidence-based medicine.
RESULTS A total of 212 items of off-label use supported by sufficient evidence were included, including 20 items about CTL-A4 inhibitors, 179 items about PD-1 inhibitors and 13 items about PD-L1 inhibitors.
CONCLUSION This guide clarify the off-label use of ICIs with sufficient evidence, and provides a practical reference for ICIs off-label use management.

FullText(HTML)

References (15)

Cited By

Turn off MathJax

Article Contents

Practice Guideline for Off-label Use of Immune Checkpoint Inhibitors

Graphical Abstract

Abstract

Catalog

Export File

Citation

Format

Content